A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
<p>Background: This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and oral rucaparib, a poly (ADP-ribose) polymerase inhibitor, combined with chemotherapy in patients with advanced solid tumours.</p> <p>Methods: Initially, patients received escalati...
Main Authors: | Wilson, R, Jeffry Evans, T, Middleton, M, Molife, L, Spicer, J, Dieras, V, Roxburgh, P, Giordano, H, Jaw-Tsai, S, Goble, S, Plummer, R |
---|---|
Format: | Journal article |
Published: |
Cancer Research UK
2017
|
Similar Items
-
Copper-mediated radiosynthesis of [18F]rucaparib
by: Chen, Z, et al.
Published: (2021) -
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
by: Plummer, R, et al.
Published: (2013) -
Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
by: Kaltsas, G, et al.
Published: (2002) -
Combination chemotherapy for myelomatosis.
by: Clarke, M, et al.
Published: (1992) -
Understanding resistance to combination chemotherapy
by: Pritchard, Justin R., et al.
Published: (2014)